Laureate to Develop Trop-2 Targeting Antibody for ARIUS

February 12, 2008
BioPharm International Editors

Laureate Pharma, Inc. (Princeton, NJ) has entered into a cGMP contract manufacturing agreement with ARIUS Research, Inc. (Toronto, Canada) for its Trop-2 signal transduction antibody program.

Laureate Pharma, Inc. (Princeton, NJ) has entered into a cGMP contract manufacturing agreement with ARIUS Research, Inc. (Toronto, Canada) for its Trop-2 signal transduction antibody program. Under the agreement, Laureate will produce ARIUS’s IgG1 humanized antibody. ARIUS’s Trop-2 antibody program targets a novel marker that has been linked to aggressive cancers including pancreatic, colon, breast, and prostate cancer.

Laureate Pharma releaseARIUS release

Related Content:

News